 Organogenesis NASDAQ:ORGO was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical Sports Medicine markets. ... 